Abstract
Despite recent controversy, preimplantation genetic diagnosis (PGD) for aneuploidies is becoming a practical means in assisted reproduction technology (ART) to select embryos with higher developmental potential for improving in vitro fertilization (IVF) effectiveness. Available PGD experience for chromosomal disorders shows that at least half of the oocytes and embryos obtained from poor prognosis IVF patients are aneuploid and clearly should not be transfered, which makes PGD of direct clinical relevance to IVF. The current selection of embryos for transfer, based on morphologic criteria, cannot guarantee avoiding the transfer of aneuploid embryos destined to be lost in pre and post-implantation developments. This may explain the fact that thousands of PGD cycles have been performed for poor prognosis IVF patients, including those of advanced reproductive age, with repeated IVF failure, and recurrent spontaneous abortions, with the majority demonstrating a positive impact of preselection of aneuploid-free embryos on IVF outcome. The present review demonstrates that because of the potential benefit of PGD for chromosomal disorders, it may soon become a valuable addition to the required standards of IVF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
